TELA Bio Analysts Cut Their Forecasts After Q4 Results

Group 1 - TELA Bio, Inc. reported a quarterly loss of 17 cents per share, beating the analyst consensus estimate of 18 cents per share [1] - The company reported quarterly sales of $20.869 million, missing the analyst consensus estimate of $21.047 million [1] - TELA Bio anticipates first-quarter sales of $18.500 million, lower than market estimates of $21.277 million [1] - Following the earnings announcement, TELA Bio shares declined by 9.4% to close at $0.6901 [1] Group 2 - Canaccord Genuity analyst Caitlin Roberts maintained a Buy rating on TELA Bio but lowered the price target from $4 to $2 [3] - Lake Street analyst Frank Takkinen also maintained a Buy rating while reducing the price target from $3 to $2 [3] - Piper Sandler analyst Matt O'Brien maintained a Neutral rating and lowered the price target from $1.25 to $1 [3]